Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

A cancer patient’s gratitude toward his Vanderbilt-Ingram Cancer Center (VICC) physician led to a star-studded concert to benefit the Cancer Center. Colon cancer survivor and country artist Wade Hayes was joined by six-time CMA and ACM Female Vocalist of the Year Miranda Lambert, four-time Grammy and CMA Award-winning artist Steve Wariner and Kix Brooks, CMA […]

Patients with small intestine neuroendocrine tumors often have mesenteric tumor deposits (MTDs) in the abdomen – discrete tumor nodules that are not connected to the primary tumor. The clinical significance of these tumor deposits has not been thoroughly investigated, and they are not included in the American Joint Committee on Cancer (AJCC) staging system for […]

Metastatic pancreatic cancer — cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths — changes its metabolism and is “reprogrammed” for optimal malignancy, according to new findings reported Jan. 16 in Nature Genetics. It may be possible to reverse the malignant reprogramming to treat metastatic pancreatic cancer, […]

Despite dramatic recent advances in treatment, colorectal cancer killed more than 49,000 Americans last year, according to the National Cancer Institute, making it the second most lethal malignancy after cancers of the lung and bronchus. Determined to reduce the death toll, researchers at Vanderbilt University Medical Center recently put on their 3-D “glasses” and took […]

Vanderbilt’s Robert Coffey Jr., M.D.

The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.

The Vanderbilt-Ingram Cancer Center (VICC) announces a funding opportunity to catalyze innovative, collaborative, ovarian cancer-related projects. The goal of this award is to provide funding for generation of preliminary data required for the submission of an external, ovarian cancer-relevant grant application (e.g.

Description of Program Applications are being solicited for support by the American Cancer Society‐Institutional Research Grant (IRG). These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have external grant support. The ACS defines junior faculty as investigators at the rank of assistant […]

Applications are being solicited for the Vanderbilt-Ingram Cancer Center (VICC) Cancer Early Detection and Prevention Initiative. These funds are designed to provide money to support creating a nurturing environment for basic and clinical research investigations in the field of cancer early detection and prevention (CEDP). The immediate goal of the Initiative is to expand research, […]